Efgartigimod May Improve Myasthenia Gravis via Antibodies

Researchers find that the drug's impact on antibody function correlates with clinical improvements in some patients.

Updated on Oct. 29, 2026 in Alzheimer’s

A clear laboratory vial with a biological sample sits on a sterile stainless-steel surface, highlighting precise medical research. — Researchers have identified that the effectiveness of the drug efgartigimod in treating myasthenia gravis depends on how it modifies specific antibody functions. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical diagnostic tests will improve your personal healthcare outcomes?

Researchers have discovered that clinical improvements from the drug efgartigimod in myasthenia gravis patients are linked to how well the medication reduces specific antibody functions. This finding may eventually help clinicians better understand why some patients respond more effectively to the treatment than others.

Why it matters

Understanding the functional impact of efgartigimod on antibodies suggests that clinical success depends on more than just the total reduction of immunoglobulin G levels. This insight could help refine how specialists monitor treatment efficacy in the future.

In an analysis of 150 serum samples from 50 patients who participated in the Phase 3 ADAPT trial, researchers observed that responders showed significant reductions in complement activation and receptor internalization. These preliminary results link antibody functional modulation to clinical improvements on standardized scales.

The players

Yale

An academic research institution where scientists conducted this re-examination of trial data.

FDA

The federal agency responsible for overseeing the safety and efficacy of medical treatments in the United States.

The details

Efgartigimod works by reducing total immunoglobulin G (IgG) levels, which are often elevated in patients with myasthenia gravis. By using live cell-based assays, researchers found that the drug also limits the ability of antibodies to trigger complement activation and receptor internalization. Patients who showed the greatest clinical improvement experienced these specific functional reductions, regardless of their baseline antibody titers.

December 2021: FDA approved efgartigimod for the treatment of generalized myasthenia gravis.
Day 29: Point of maximum IgG reduction observed during the study.
Day 57: Point at which IgG levels were found to be re-established.

Health Landscape

The ADAPT trial established the foundational efficacy of efgartigimod for managing generalized myasthenia gravis. This new analysis moves beyond the initial trial metrics to investigate the precise biological mechanisms that dictate why the treatment succeeds for some individuals.

These findings are currently limited to research settings and do not yet change how you should approach or monitor your current treatment plan. If you have questions about your specific response to therapy, discuss them with your neurologist to ensure your care plan remains effective.

The takeaway

While clinical response to efgartigimod is linked to specific changes in antibody function, these findings require further validation in larger studies. If you are receiving this therapy, continue to track your symptom patterns using your standardized assessment tools and share those updates with your doctor.